The impact of injecting drug use status on hepatitis C-related referral and treatment
- 7 January 2005
- journal article
- research article
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 77 (1) , 81-86
- https://doi.org/10.1016/j.drugalcdep.2004.07.002
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001International Journal of Epidemiology, 2003
- Australian women's experiences of living with hepatitis C virus: Results from a cross‐sectional surveyJournal of Gastroenterology and Hepatology, 2003
- Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patientsAIDS, 2003
- Health-State Utilities and Quality of Life in Hepatitis C PatientsAmerican Journal of Gastroenterology, 2003
- Current therapy for hepatitis C: pegylated interferon and ribavirinClinics in Liver Disease, 2003
- Prevention and treatment of hepatitis C in injection drug usersHepatology, 2002
- Is severe liver disease a common outcome for people with chronic hepatitisC?Journal of Gastroenterology and Hepatology, 2002
- Comparison of cause-specific mortality between respondents and nonrespondents in a population-based prospective studyJournal of Clinical Epidemiology, 2002
- Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology, 1998
- A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis CQuality of Life Research, 1997